Published in Proc Natl Acad Sci U S A on December 07, 2009
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med (2010) 1.69
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
An important role of lymphatic vessel activation in limiting acute inflammation. Blood (2011) 1.62
Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol (2010) 1.61
IL-17 and VEGF are necessary for efficient corneal nerve regeneration. Am J Pathol (2011) 1.21
The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc (2011) 1.06
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol (2012) 1.06
Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem (2011) 0.96
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis (2014) 0.91
AP1 transcription factors in epidermal differentiation and skin cancer. J Skin Cancer (2013) 0.89
Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med (2014) 0.89
Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol (2013) 0.86
Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes (2013) 0.85
Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma. Graefes Arch Clin Exp Ophthalmol (2014) 0.84
An important role of the SDF-1/CXCR4 axis in chronic skin inflammation. PLoS One (2014) 0.83
Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Front Genet (2015) 0.82
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol (2013) 0.81
Capillaroscopy in psoriatic and rheumatoid arthritis: a useful tool for differential diagnosis. Arthritis (2013) 0.80
VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 mice. J Dermatol Sci (2013) 0.79
Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone. PLoS One (2013) 0.77
Vascular pathology in multiple sclerosis: mind boosting or myth busting? Exp Transl Stroke Med (2011) 0.76
VEGF involvement in psoriasis. Clujul Med (2015) 0.76
Low-molecular-weight hyaluronan (LMW-HA) accelerates lymph node metastasis of melanoma cells by inducing disruption of lymphatic intercellular adhesion. Oncoimmunology (2016) 0.75
Keratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin condition. Biomol Ther (Seoul) (2015) 0.75
Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice. BMC Complement Altern Med (2016) 0.75
Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. J Invest Dermatol (2014) 0.75
Three-dimensional model of mouse epidermis for experimental studies of psoriasis. Acta Naturae (2013) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Angiogenesis in health and disease. Nat Med (2003) 14.02
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Angiogenesis. Annu Rev Med (2006) 6.94
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 4.94
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 4.90
B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity (2006) 4.04
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 3.18
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood (2001) 2.39
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J (2004) 2.27
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 2.03
Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol (2004) 1.84
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2004) 1.82
IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol (2003) 1.56
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol (2005) 1.45
Current and future management of psoriasis. Lancet (2007) 1.29
Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol (2007) 1.26
Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res (2004) 1.23
Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol (2004) 1.17
Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol (2008) 1.15
TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene (2004) 1.11
Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med (2006) 1.09
Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol (2008) 1.05
TNFalpha shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev (2009) 1.04
Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol (2008) 1.01
Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep (2005) 0.94
Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med (2008) 0.92
Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des (2006) 0.89
ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs (2008) 0.88
c-Jun and JunB are essential for hypoglycemia-mediated VEGF induction. Ann N Y Acad Sci (2006) 0.86
Nonstandard and off-label therapies for psoriasis. Clin Dermatol (2008) 0.86
Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res (2002) 0.86
Significance of the S100A4 protein in psoriasis. J Invest Dermatol (2010) 0.84
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J (2002) 5.07
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol (2002) 4.52
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum (2008) 4.08
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
The molecular clock mediates leptin-regulated bone formation. Cell (2005) 3.88
T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J (2003) 3.82
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol (2003) 3.35
TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques (2009) 3.35
The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron (2004) 3.33
Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol (2005) 3.21
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn (2002) 3.10
Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem (2001) 3.10
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev (2002) 2.99
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol (2004) 2.81
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem (2004) 2.66
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet (2004) 2.47
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J (2004) 2.27
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem (2007) 2.22
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J (2002) 2.15
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet (2002) 2.07
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 2.03
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci (2002) 1.99
Endothelialized networks with a vascular geometry in microfabricated poly(dimethyl siloxane). Biomed Microdevices (2004) 1.97
Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci (2003) 1.94
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev (2006) 1.84
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol (2012) 1.81
VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood (2007) 1.78
The lymphatic system in health and disease. Lymphat Res Biol (2008) 1.78
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol (2004) 1.77
Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol (2004) 1.77
Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 1.76
New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol (2006) 1.76
The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol (2002) 1.75
Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol (2002) 1.75
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis. J Leukoc Biol (2006) 1.72
Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell (2003) 1.71
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med (2010) 1.69
Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood (2010) 1.67
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J (2003) 1.67
Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem (2003) 1.66
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood (2010) 1.66
Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell (2005) 1.62
An important role of lymphatic vessel activation in limiting acute inflammation. Blood (2011) 1.62
Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology (2013) 1.59
p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle (2007) 1.57
Pathways targeting tumor lymphangiogenesis. Clin Cancer Res (2006) 1.56
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature (2008) 1.52
MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol (2004) 1.51
Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis (2011) 1.51
Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene (2003) 1.48
Lymphangiogenesis and cancer metastasis. J Cell Mol Med (2009) 1.47
The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J (2004) 1.46
Mechanisms of lymphatic metastasis. J Clin Invest (2014) 1.46
Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol (2005) 1.45
Quantitative imaging of lymphatic function with liposomal indocyanine green. Cancer Res (2010) 1.43
A critical role of placental growth factor in the induction of inflammation and edema formation. Blood (2002) 1.38
Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol (2002) 1.35
The limited role of NH2-terminal c-Jun phosphorylation in neuronal apoptosis: identification of the nuclear pore complex as a potential target of the JNK pathway. J Cell Biol (2005) 1.32
Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol (2008) 1.32
Mouse models for liver cancer. Mol Oncol (2013) 1.31
Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol (2006) 1.31
Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene (2002) 1.30
Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest (2002) 1.30
Prox1, master regulator of the lymphatic vasculature phenotype. Cell Tissue Res (2003) 1.28
Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene (2002) 1.27